WHO seeks 'additional clarifications' from Bharat Biotech for Covaxin to conduct final 'risk-benefit assessment'
![](https://img.etimg.com/thumb/msid-87288990,width-1070,height-580,imgsize-30482,overlay-economictimes/photo.jpg)
"The TAG met today (26 October 2021) and decided that additional clarifications from the manufacturer are needed to conduct a final EUL risk-benefit assessment for global use of the vaccine," the WHO said in an email response to a question by PTI on the decision regarding the Emergency Use Listing of Covaxin.
via Economictimes
Post a Comment